TFF Pharmaceuticals (TFF Pharmaceuticals) Cash-to-Debt : 47.22 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is TFF Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. TFF Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 47.22.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, TFF Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for TFF Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

TFFP' s Cash-to-Debt Range Over the Past 10 Years
Min: 47.22 Med: No Debt Max: No Debt
Current: 47.22

During the past 7 years, TFF Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 47.22. And the median was No Debt.

TFFP's Cash-to-Debt is ranked better than
72.06% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs TFFP: 47.22

TFF Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for TFF Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

TFF Pharmaceuticals Cash-to-Debt Chart

TFF Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

86.97

47.22

TFF Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															86.97	70.61	49.76	72.04	47.22

Competitive Comparison of TFF Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, TFF Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TFF Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TFF Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where TFF Pharmaceuticals's Cash-to-Debt falls into.

TFF Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

TFF Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.478	/	(0.084	+	0.032)
	=	47.22

TFF Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.478	/	(0.084	+	0.032)
	=	47.22

TFF Pharmaceuticals (NAS:TFFP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

TFF Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of TFF Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

TFF Pharmaceuticals (TFF Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TFF Pharmaceuticals Inc (NAS:TFFP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.tffpharma.com

TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.

Executives

Carlson Capital L P	10 percent owner	2100 MCKINNEY AVE, STE 1900, DALLAS TX 75201
Clint Duane Carlson	10 percent owner	2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Zamaneh Mikhak	officer: Chief Medical Officer	1751 RIVER RUN, SUITE 400, C/O TFF PHARMACEUTICALS, INC., FORT WORTH TX 76107
Robert S Mills	director	8 MISTY BROOK LANE, NEW FAIRFIELD CT 06812
Kirk Allen Coleman	officer: CFO, Secretary, and Treasurer	2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
Stephen Rocamboli	director	C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Asgard Investment Corp. Ii	10 percent owner	2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Double Black Diamond Offshore Ltd	10 percent owner	CITCO FUND SERVICES, 89 NEXUS WAY, P.O. BOX 31106, CAMANA BAY E9 KY-1205
Harlan F Weisman	director	C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Brandi Roberts	director	12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Fletcher Aaron G.l.	director	40 GUEST STREET, BOSTON MA 02135
Randy H Thurman	director	222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Glenn R. Mattes	director, officer: President and CEO	200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Malcolm Fairbairn	director	C/O ASCEND CAPITAL, LLC, 4 ORINDA WAY, SUITE 200-C, ORINDA CA 94563
Lung Therapeutics, Inc.	10 percent owner	P.O. BOX 150183, AUSTIN TX 78715